"Doudna's Aclaris CEO Steps Down, Secures $114M Liver Disorder Deal with Genevant"

Jennifer Doudna's lab published a study detailing how antibody fragments can target virus-like particles with gene editing machinery to T cells, co-founding genetic medicine delivery startup Aza­lea Ther­a­peu­tics, which has raised $10 million.